Organon & Co. (OGN)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 18.55 |
| Open | 18.69 |
| Bid | 16.80 x 1000 |
| Ask | 20.00 x 1000 |
| Day's range | 18.69 - 19.04 |
| 52-week range | 10.84 - 24.58 |
| Volume | |
| Avg. volume | 2,340,598 |
| Market cap | 4.861B |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | 4.74 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.12 (5.93%) |
| Ex-dividend date | 23 Feb 2024 |
| 1y target est | N/A |
- Business Wire
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
JERSEY CITY, N.J., April 08, 2024--Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
- Business Wire
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
SHANGHAI, China & JERSEY CITY, N.J., April 08, 2024--Organon and Henlius announce that Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoint
- Business Wire
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
JERSEY CITY, N.J., February 20, 2024--Organon Announces HADLIMA Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
© 2024 Yahoo. All rights reserved.